Welcome to our dedicated page for Silence Therapeutics news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics stock.
Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics (AIM: SLN, Nasdaq: SLN) has launched an online game, Blood Run Beta, to raise awareness for thalassemia ahead of International Thalassemia Day on May 8, 2021. The game aims to educate players about thalassemia's impact, particularly fatigue, and encourages sharing scores on social media using #BloodRunBeta. Silence is also partnering with the Thalassaemia International Federation to support activities for the event, with this year's theme focusing on health inequalities in the thalassemia community. The initiative aims to enhance public understanding of this rare disorder.
Silence Therapeutics has achieved a significant milestone in its RNAi collaboration with Mallinckrodt, triggering a $2 million payment related to the SLN500 C3 targeting program. This payment highlights the ongoing success of their partnership focused on complement-mediated diseases.
Silence is progressing with Investigational New Drug (IND) enabling studies for SLN501 within this collaboration. The agreement includes a potential for $2 billion in total milestone payments and tiered royalties on net sales, reflecting a financially beneficial arrangement for Silence Therapeutics.
Silence Therapeutics plc (AIM:SLN, Nasdaq:SLN) has released a new review in Cardiovascular Research, focusing on RNA therapeutics for preventing cardiovascular disease linked to high lipoprotein(a) (Lp(a)) levels, a condition affecting around 20% of the global population. The review emphasizes RNA interference (RNAi) therapies, especially the lead candidate SLN360, which aims to lower Lp(a) levels significantly. Promising pre-clinical results indicate over 90% reduction in Lp(a) with a strong safety profile. Data from the ongoing APOLLO Phase 1 trial is expected in late 2021.
Silence Therapeutics, listed under AIM: SLN and Nasdaq: SLN, announces its participation in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021. CEO Mark Rothera will present an overview followed by a Q&A session at 8:45 a.m. EDT. Investors can access a live webcast on the company’s website, with an archived replay available after the event. Silence Therapeutics focuses on developing innovative siRNA therapeutics targeting diseases with significant unmet needs, including SLN360 and SLN124, aimed at cardiovascular risk and iron loading anemias, respectively.
Silence Therapeutics, trading under the symbol SLN, published its audited full-year results for 2020, showcasing substantial advancements in its mRNAi GOLD™ platform.
Significant developments include the initiation of Phase 1 studies for SLN360 and SLN124, with SLN360 receiving FDA IND approval. Financially, the company ended 2020 with £37.4m in cash and raised $45m in funding. A pivotal collaboration with AstraZeneca yielded an upfront payment of $20m, with potential future milestones up to $400m. Silence aims to deliver 2-3 INDs annually starting in 2023, underlining its commitment to innovation.
Silence Therapeutics will present at the Barclays Global Healthcare Conference on March 11 at 4:10 p.m. EST. The presentation will be led by President and CEO Mark Rothera, providing an overview of the company’s developments in siRNA therapeutics for significant unmet medical needs. A live webcast will be available on the company’s website, with an archived replay post-conference. Silence's innovative RNAi technology targets the silencing of disease-related genes.
Silence Therapeutics and Mallinckrodt have commenced work on a third research target as part of their RNAi collaboration for complement-mediated diseases. Silence will receive a $2 million milestone payment, contributing to a potential total of $2 billion in milestone payments across three targets. Additionally, Silence stands to gain tiered double-digit royalties on net sales for each candidate developed. This collaboration is aimed at leveraging Silence’s mRNAi GOLD™ platform to develop therapeutics that inhibit the complement cascade, addressing significant medical needs.
Silence Therapeutics will participate in two virtual investor conferences in March 2021 to provide important business updates. The Cowen 41st Annual Health Care Conference is scheduled for March 1 at 10:20 AM EST, while the H.C. Wainwright Global Life Sciences Conference will be available on-demand on March 9. Interested investors can access live webcasts and archived replays through the company's website. Silence Therapeutics specializes in developing siRNA therapeutics for significant unmet medical needs, with key products including SLN360 and SLN124.
Silence Therapeutics, AIM: SLN and Nasdaq: SLN, will present at the 2021 SVB Leerink Global Healthcare Conference on February 26th at 9:20 a.m. EST. CEO Mark Rothera will provide a company update, focusing on their innovative siRNA therapeutics aimed at significant unmet medical needs. A live webcast will be available on Silence's website, with a replay following the event. The company's proprietary platform is pivotal for developing medicines targeting disease-associated genes, including product candidates SLN360 and SLN124.
Silence Therapeutics has commenced dosing in the Phase I clinical trial of SLN360, targeting cardiovascular disease linked to elevated lipoprotein(a) levels. The APOLLO trial aims to assess the safety, tolerability, and pharmacokinetics of SLN360 in approximately 88 participants with Lp(a) levels ≥60 mg/dL. Results from the initial dosing phase are expected later this year. SLN360, a gene silencing therapy, seeks to lower elevated Lp(a) and reduce associated heart disease risks.